Summit Therapeutics Inc. (SMMT) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low10.8·High10.8
P/FCF
N/A
—
5yr avg: N/A
30Y Low42.8·High42.8
P/B Ratio
↑
19.46
+17% vs avg
5yr avg: 16.62
30Y Low0.9·High64.3
ROE
↓
-206.1%
↓+5% vs avg
5yr avg: -217.4%
30Y Low-206%·High31%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SMMT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Summit Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13.3B | $13.1B | $12.8B | $1.6B | $822M | $248M | $327M | $53M | $115M | $898M | $644M |
| Enterprise Value | $13.1B | $12.9B | $12.7B | $1.7B | $992M | $179M | $261M | $3M | $79M | $870M | $609M |
| P/E Ratio → | -11.91 | — | — | — | — | — | — | — | 12.09 | — | — |
| P/S Ratio | — | — | — | — | 1166.67 | 137.16 | 379.96 | 83.11 | 2.01 | 63.41 | 223.76 |
| P/B Ratio | 19.46 | 19.85 | 32.99 | 20.82 | 6.49 | 2.98 | 4.11 | 0.86 | 2.05 | 64.27 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 42.77 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 42.46 |
P/E links to full P/E history page with 30-year chart
SMMT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 1408.27 | 99.01 | 303.27 | 5.16 | 1.39 | 61.40 | 211.58 |
| EV / EBITDA | — | — | — | — | — | — | — | — | 10.81 | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | 8.18 | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 40.45 |
SMMT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -206.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | -257.0% | 100.0% | 100.0% | 96.8% | 98.8% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | -11259.8% | -4764.3% | -8330.9% | -6766.4% | 9.4% | -182.3% | -1078.6% |
| Net Profit Margin | — | — | — | — | -11185.9% | -4897.8% | -6127.6% | -3779.0% | 19.0% | -201.4% | -788.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -206.1% | -206.1% | -94.9% | -601.8% | -75.1% | -108.9% | -75.0% | -40.9% | 31.2% | -593.7% | -176.6% |
| ROA | -181.9% | -181.9% | -69.3% | -141.8% | -20.3% | -82.1% | -59.2% | -31.0% | 14.0% | -46.3% | -54.9% |
| ROIC | -220.2% | -220.2% | -78.6% | -32.9% | -38.2% | -465.4% | -424.3% | -198.0% | 132.6% | — | — |
| ROCE | -204.2% | -204.2% | -73.3% | -22.2% | -22.2% | -101.2% | -96.7% | -67.3% | 9.4% | -57.7% | -92.4% |
SMMT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $225M exceeds total debt of $21M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 1.37 | 4.10 | 0.03 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.31 | -0.25 | 0.45 | 1.34 | -0.83 | -0.83 | -0.81 | -0.63 | -2.04 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -4.80 | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -2.33 |
| Interest Coverage | — | — | -26.48 | -4.23 | -18.02 | -314.45 | -206.49 | -695.65 | 15.65 | — | -28.83 |
Net cash position: cash ($225M) exceeds total debt ($21M)
SMMT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Summit Therapeutics Inc.'s current ratio of 9.87x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.30x to 9.87x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.87 | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 3.34 | 6.27 | 3.63 | 1.56 | 3.06 |
| Quick Ratio | 9.87 | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 3.93 | 6.27 | 3.63 | 1.56 | 3.06 |
| Cash Ratio | 9.77 | 9.77 | 9.88 | 9.13 | 8.99 | 2.80 | 3.34 | 5.05 | 2.09 | 1.24 | 3.22 |
| Asset Turnover | — | — | — | — | 0.00 | 0.02 | 0.01 | 0.01 | 0.73 | 0.19 | 0.06 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 3169.09 | 1740.26 | 4323.55 | 183.72 | 50.80 | 240.37 | 583.63 |
SMMT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Summit Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 8.3% | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 2.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $748M | $719M | $620M | $193M | $92M | $70M | $33M | $86M | $65M | $62M |
Peer Comparison
Compare SMMT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SMMTYou | $13B | -11.9 | — | — | — | — | -206.1% | -220.2% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 TNGX | $3B | -27.0 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 EXEL | $12B | 16.6 | 12.7 | 13.9 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
Full SMMT Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SMMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMMT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SMMT vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonSMMT — Frequently Asked Questions
Quick answers to the most common questions about buying SMMT stock.
What is Summit Therapeutics Inc.'s P/E ratio?
Summit Therapeutics Inc.'s current P/E ratio is -11.9x. The historical average is 12.1x.
What is Summit Therapeutics Inc.'s ROE?
Summit Therapeutics Inc.'s return on equity (ROE) is -206.1%. The historical average is -76.9%.
Is SMMT stock overvalued?
Based on historical data, Summit Therapeutics Inc. is trading at a P/E of -11.9x. Compare with industry peers and growth rates for a complete picture.